ves esta página sin formato por que esta hecha cumpliendo el estándar web CSS 2.
tú navegador no soporta este estándar, o tienes dicho soporte desactivado.
si estas en el primer caso, actualízate. merece mucho la pena.

MI PRIMERA BITACORA

Temas
  • Salud
  • <Noviembre 2018
    Lu Ma Mi Ju Vi Sa Do
          1 2 3 4
    5 6 7 8 9 10 11
    12 13 14 15 16 17 18
    19 20 21 22 23 24 25
    26 27 28 29 30    
                 


    WWW http://prueba.blogalia.com

    Blogs informática médica
    Medical Informatics
    Julio Bonis MD

    Blogs mantenidos por médicos
    Adolescentes
    Consulta joven virtual
    Copensalud
    Diario de un residente de cardiologia de Valencia
    Diario de un médico del SAS
    El bisturí
    Endocitosis de red
    La Dama de las Artemias
    Lluisalcanyis.org
    Nuevos modelos de gestión
    Primablog
    Una de médicos
    Vigilando la gripe
    Bitácora de Webcalidad
    Vila-real, t´estime

    Blogs de Diario Medico
    Panorama desde el puente
    La Semeca en Guatemala
    Política de salud de la UE
    Salud pública en acción
    En los pasillos de la bioética
    La Oncología Médica al día
    Congreso AHA 2005
    La Oncología Médica al día
    Ahí viene la plaga
    La Jungla de Cristal
    Ahí viene la plaga
    Síndrome de abstinencia

    Blogs mantenidos por enfermeros
    Blog Maite Martínez Lao
    Jetlageando

    Blogs mantenidos por pacientes y usuarios
    Fibromialiadori
    Hepatitis C Iberica
    HOSPITAL DE LA RIBERA DE ALZIRA, LA VERGÜENZA

    Otros Blogs de Salud
    Avenir de la Santé

    Blogs "super"
    atalaya
    eCuaderno
    cosa humeda

    Blogs femeninos
    A contraluz
    Allyenna
    Benko
    Biblioteca de Babel
    Evasivas
    Chicaconfaldaroja
    Lapetiteclaudine
    Maria milonas
    Mi libro de arena
    Yolandax

    Blogs de políticos
    Ramón Basas PSC-PSOE
    Rosa Maria Bonàs i Pahissa ERC
    Miquel Bofill ERC
    Gustavo de Arístegui PP
    Rafael Estrella PSOE
    Francesc Ferrer i Gironés ERC
    Carlos González PSOE
    Esteban González Pons PP
    J J Ibarretxe PNV
    Miquel Iceta PSOE-PSC
    L Martinez Oblanca PP
    Manel Mas PSOE-PSC
    J L Moreno PP
    L Muñoz Santamaría PSOE-PSC
    Enric Nomdedéu BNV
    J Puig Cordón ERC
    Alicia Sánchez PP
    Maria San Gil PP
    Francisco Toledo
    J A Torres Mora PSOE
    Francisco Valverde PSOE

    TRANSLATE

    Blogalia

    Blogalia


    ©2003 jrnegre

    AVISO
    Inicio > Historias > El NICE inglés y Yescarta 2018-09-01

    El NICE inglés y Yescarta

    Hace muy pocos días, el NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) inglés ha publicado un documento para pública consulta sobre la  efectiviad de Yescarta en su indicación solicitada: tratamiento de adultos con linfoma difuso de células B grandes o mediástinico primario con fracaso tras al menos dos líneas de tratamientos.


    Este documento concluye, de modo provisional:

     1 Recommendations 

    1.1 Axicabtagene ciloleucel is not recommended, within its anticipated marketing authorisation, for treating relapsed or refractory diffuse large Bcell lymphoma or primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.

     1.2 This recommendation is not intended to affect treatment with axicabtagene ciloleucel that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. Why the committee made these recommendations

    Why the committee made these recommendations

     There is no standard treatment for relapsed or refractory diffuse large Bcell lymphoma or primary mediastinal large B-cell lymphoma after 2 or more systemic therapies. Best supportive care is used and usually includes salvage chemotherapy. Evidence from a small, single-arm study suggests that people having axicabtagene ciloleucel have good response rates, overall survival and progression-free survival. But, there are no direct data comparing axicabtagene ciloleucel with salvage chemotherapy (referred to as best supportive care by the company). This means that the exact size of the benefit of axicabtagene ciloleucel compared with salvage chemotherapy is unknown. Axicabtagene ciloleucel meets NICE’s criteria to be considered a lifeextending treatment at the end of life. However, all the cost-effectiveness estimates are above the range normally considered to be a cost-effective use of NHS resources. Axicabtagene ciloleucel does not meet the criteria for inclusion in the Cancer Drugs Fund. Because of this, axicabtagene ciloleucel is not recommended.


    -----

    Cost-effectiveness results 

    The range of the cost-effectiveness estimates is wide and all are above £50,000 per QALY gained 


    3.23 The company’s deterministic base case showed that the incremental costeffectiveness ratio (ICER) for axicabtagene ciloleucel compared with salvage chemotherapy was over £50,000 per QALY gained. The exact ICER is commercial in confidence and cannot be reported here. The ERG made some changes to the company’s model to reflect its preferred basecase analysis, specifically: 




    These changes resulted in an ERG exploratory base-case ICER that was over £100,000 per QALY gained. The committee noted the wide range between the company’s and ERG’s base-case ICERs. It agreed that there was a high degree of uncertainty associated with both the company’s and ERG’s estimates because of the limitations in the data for the comparator and the immature survival data for axicabtagene ciloleucel. The committee concluded that based on the data and analyses presented to it, the cost-effectiveness estimates were all above £50,000 per QALY gained.


    2018-09-01 06:16 | 6 Comentarios


    Referencias (TrackBacks)

    URL de trackback de esta historia http://prueba.blogalia.com//trackbacks/77543

    Comentarios

    1
    De: homenicedesign Fecha: 2018-09-25 15:37

    Extraordinary substance material and awesome design. Your site merits the majority of the positive input it's been getting.
    www.homenicedesign.com



    2
    De: style frontier Fecha: 2018-09-27 09:01

    Thank you very much for this useful article. I like it.
    www.style-frontier.com



    3
    De: Sweety Patel Fecha: 2018-10-02 10:11

    It is interesting to read NICE Rejects Blood Cancer Drug Yescarta. Please post more article like this,

    Sweety Patel



    4
    De: Anika Kaur Fecha: 2018-10-02 10:53

    Good article and really nice way of writing it. I'm expecting more post like this.

    http://www.anikakaur.com/



    5
    De: sceneunited Fecha: 2018-10-02 13:55

    This post has helped me for an article which I am writing. Thank you for giving me another point of view on this topic. Now I can easily complete my article.
    www.sceneunited.com



    6
    De: independent mumbai escorts Fecha: 2018-11-13 05:37

    Welcome to Mumbaihotcollection.com, home of the finest Mumbai escorts in Mumbai area. Our Mumbai escorts are the finest Mumbai has to offer and will provide an unforgettable Mumbai Escort experience!
    Escorts in mumbai
    Escort service in mumbai
    Mumbai escorts
    Mumbai call girls
    Call girls in mumbai
    Escorts mumbai
    Mumbai pictures
    Celebrity escorts
    quick available escorts
    Andheri escorts
    Juhu escorts
    Churchgate escort
    Vile Parle escorts
    Marina drive escorts
    Nariman point escorts
    Bandra escorts
    Mumbai central escorts



    Nombre
    Correo-e
    URL
    Dirección IP: 54.82.73.21 (0ad60ea5ab)
    Comentario
    ¿Cuánto es: diez mil + uno?

    portada | subir

    Listed on BlogShares